Effect of Cu(II) Coordination Compounds on the Activity of Antioxidant Enzymes Catalase and Superoxide Dismutase in Patients with Colorectal Cancer

• Authors: Katarzyna Kubiak , Katarzyna Malinowska , Ewa Langer , Łukasz Dziki , Adam Dziki , Ireneusz Majsterek
• Languages of publication: EN

Abstracts

EN

Colorectal cancer (CRC) is a serious medical and economical problem of our times. It is the most common gastrointestinal cancer in the world. In Poland, the treatment and detection of CRC are poorly developed and the pathogenesis is still unclear. One hypothesis suggests a role of reactive oxygen species (ROS) in the pathogenesis of CRC. Experimental studies in recent years confirm the participation of ROS in the initiation and promotion of CRC.The aim of the study was to examine the effect of the following coordination compounds coordination compounds: dinitrate (V) tetra(3,4,5-trimethyl-N1-pyrazole-κN2) copper(II), dichloro di(3,4,5-trimethyl-N1-pyrazole-κN2) copper(II), dinitrate (V) di(1,4,5-trimethyl-N1-pyrazole-κN2) copper(II), dichloro di(1,3,4,5-tetramethyl-N1-pyrazole-κN2) copper(II) on the activity of antioxidant enzymes superoxide dismutase (SOD, ZnCu-SOD) and catalase (CAT) in a group of patients with colorectal cancer (CRC) and in the control group consisting of patients with minor gastrointestinal complaints.Material and methods. The study was conducted in 20 patients diagnosed with colorectal cancer at the age of 66.5±10.2 years (10 men and 10 women) versus the control group of 20 people (10 men and 10 women) aged 57.89±17.10 years without cancer lesions in the biological material - hemolysate prepared in a proportion of 1ml of water per 1 ml of blood. CAT activity was measured by the Beers method (1952), while SOD activity was measured by the Misra and Fridovich method (1972).Results. We found that patients with CRC showed a statistically significant decrease of SOD and CAT activity (CAT - 12,75±1.97 U/g Hb, SOD - 1111.52±155.52 U/g Hb) in comparison with the control group (CAT - 19.65±2,17 U/g Hb, SOD - 2046.26±507.22 U/g Hb). Simultaneously, we observed that the investigated coordination compounds of Cu(II) significantly increased the antioxidant activity of CAT and SOD in patients with CRC (mean: CAT 25.23±4.86 U/g Hb, SOD - 3075.96±940.20 U/g Hb).Conclusions. Patients with colorectal cancer are characterized by reduced activity of antioxidant enzymes catalase and superoxide dismutase which suggests impaired antioxidant barrier. Therefore, coordination compounds of Cu (II), which enhance the activity of CAT and SOD, may prove useful in the prevention and treatment of colorectal cancer.

Keywords

EN

colorectal cancer; catalase; superoxide dismutase; coordination compounds

• Publisher: De Gruyter Open
• Journal: Polish Journal of Surgery
• Year: 2011
• Volume: 83
• Issue: 3
• Pages: 155-160

Dates

published

1 - 3 - 2011

online

2 - 5 - 2011

Contributors

author

Katarzyna Kubiak

• Department of Chemistry and Clinical Biochemistry, Medical University in Łódź

author

Katarzyna Malinowska

• Department of Chemistry and Clinical Biochemistry, Medical University in Łódź

author

Ewa Langer

• Department of General and Colorectal Surgery, Medical University in Łódź

author

Łukasz Dziki

• Department of General and Colorectal Surgery, Medical University in Łódź

author

Adam Dziki

• Department of General and Colorectal Surgery, Medical University in Łódź

author

Ireneusz Majsterek

• Department of Chemistry and Clinical Biochemistry, Medical University in Łódź

References

• Bartosz G: Druga twarz tlenu. Wydawnictwo Naukowe PWN, Warszawa 2006; 376.
• Little C, O'Brian P: Intracellular GSH-peroxidase with a lipid peroxide substrate. Biophys Res Commun 1968; 31: 145-50.
• Lin TL: Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443: 787-95.
• Banaszkiewicz Z, Tojek K, Rydzkowski M i wsp.: Polipy olbrzymie jelita grubego - 10-letnie doświadczenie Valetudinaria. Post Med Klin Wojsk 2004; 9(2): 70-75.
• Banaszkiewicz Z, Tojek K, Rydzkowski M i wsp.: Polipy olbrzymie jelita grubego - 10-letnie doświadczenie, Valetudinaria. Post Med Klin Wojsk 2004; 9(2): 76-86.
• Baniukiewicz A, Dąbrowski A, Musiał WJ i wsp.: Ocena skuteczności wybranych badań przesiewowych i endoskopowych metod leczenia nowotworów jelita grubego. Prob Lek 2002; 41(4): 316-24.
• Levin B, Rozen P, Young GP: Potential pitfails in the use of surrogate endopoints in colorectal adenoma chemoprevention. J Natal Cancer Inst 2003; 95(10): 697-99.
• Dębiec-Rychter M, Liberski PP: Wybrane Zagadnienia Etiopatogenezy Nowotworów. Cancer Gent Cytogenet 1998; 11-28.
• Budzisz E, Krajewska U, Różalski M, et al.: Biological evaluation of novel Pt(II) and Pd(II) complexes with pyrazole-containing ligands. Eur J Pharm 2004; 502: 59-65.
• Schepetkin I: Decomposition of reactive oxygen species by copper(II)bis(1-pyrazolyl)methane complexes J Biol Inorg Chem 2006; 11(4): 499-513.[Crossref]
• Boixassa A, Pons J, Virgilia A, et al.: Reaction of platinum(II)derivatives with 1-hydroxyalkyl-3,5-methylpyrazole ligands. Cleavage of the N(pz)-C(sp3) bond. X-ray crystal structure of cis-(-PtCl2(HL2)2) (HL2=1-(2-hydroxyethyl)-3,5-dimethylpyrazole) and trans-(PtCl2 (dmpz)2) (dmpz=3,5-dimethylpyrazole). Inorg Chim Acta 2003; 355: 254-63.
• Driessen WL, Graaff RAG, Ochocki J, et al.: Mixed acetato-perchlorate transition metal complexes of pyrazole substituted ammonia. Crystal structure of ((acetato)(aqua)(tris(3,5-dimethyl-1-pyrazolymethyl)amine)cobalt(II))perchlorate. Inorg Chim Acta 1988; 150: 41-45.
• El-Amrani FBA, Perello L, Real JA, et al.: Oxidative DNA cleavage induced by an iron (III) flavonoid complex: Synthesis crystal structure and characterization of chlorobis(flavonolato)methanol)iron(III) complex J Inorg Biochem 2006; 100: 1208-18.
• Keter FK, et al.: Pyrazole and pyrazolyl palladium(II) and platinum(II) complexes: synthesis and in vitro evaluation as anticancer agents. A thesis submitted in partial fulfillment of the reqiurments for the degree of masters in science in the Department of Chemistry. University of the Western Cape. November 2004: 1-123.
• Ciesielska E, Malinowska K, Szmigiero L, et al.: Comparative studies on the mechanism of cytotoxic action of novel platinum (II) complexes with pyrasole ligands. Inorg Biochem 2006; 1579-85.
• Beers R, Sitzer T: Spectrophotometric method for measuring the breackolown of hydrogen peroxide by catalase. J Biol Chem 1952; 195: 133-140.
• Misra HP, Fridovich J: The role of superoxide anion in the autooxidation of epinephrine and a Simple assai for the superoxide dismutases. J Biol Chem 1972; 3170-73.
• Klimczak A, Kubiak K, Cybulska M i wsp.: Etiologia raka jelita grubego oraz bariera antyoksydacyjna ustroju Pol Merk Lek 2010; 165: 223-226.
• Beresford SA., et al.: Low fat dietary pattern and risk of colorectal cancer: The Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006; 295: 643-54.
• Papas AM: Chemoprevention for gynecological cancer high risk patients. EAGC 2nd International Congress on Gynecological Malignancies 2004; 24-25.
• Pawlicki M, Wojtukiewicz W: Rak okrężnicy. Diagnostyka, leczenie, kontrowersje. Wydawnictwo Alfa Medica Press 2006; 104-121
• Malinowska K, Gałecka E, Modranka R i wsp.: Pochodne pirazoli stosowane w lecznictwie. Pol Merk Lek 2008; 140: 151-55.
• El Amrani FBA, Perello L, Real JA, et al.: Oxidative DNA cleavage induced by an iron(III) flavonoid complex: Synthesis ctystal structure and characterization of chlorobis(flavonolato)methanolIron(III). J Inorg Biochem 2006; 100: 1208-18.
• Klimczak A, Kubiak K: Poszukiwanie nowych skutecznych leków przeciwnowotworowych. Pol Merk Lek 2009; 151: 52-57.
• Malinowska K, Modranka R, Kubiak K i wsp.: Wpływ związków koordynacyjnych na aktywność enzymów antyoksydacyjnych w chorobach nowotworowych przewodu pokarmowego. Pol Merk Lek 2009; 158: 97-100.
• Culotta V, Yang M, O'Halloran TV: Activition of superoxide dismutases: Putting the metal to the pedal. Biochim Biophys Acta 2006; 1763: 747-58.
• Michalak K, Hendrich AB: Rola lipidów błony komórkowej w zjawisku oporności wielolekowej i jego modulacji. Post Biochem 2002; 48: 208-19.
• Czeczot H, Ścibior D, Skrzycki M i wsp.: Aktywność enzymów antyoksydacyjnych u chorych z marskością wątroby. Wiad Lek 2006; 59: 762-66.
• Pasetto LM, Bortolami A, Falci C, et al.: Recent Progress in target therepy in colorectal cancer. Anticancer Res 2006; 26: 3973-81.

Identifiers

DOI

10.2478/v10035-011-0024-6